Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Merck
Colorcon
Boehringer Ingelheim

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,289,382

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,289,382
Title:Vaginal inserted estradiol pharmaceutical compositions and methods
Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
Inventor(s): Bernick; Brian A. (Boca Raton, FL), Amadio; Julia M. (Boca Raton, FL)
Assignee: TherapeuticsMD, Inc. (Boca Raton, FL)
Application Number:14/624,051
Patent Claims: 1. A pessary comprising about 25 .mu.g of 17.beta.-estradiol in a solubilizing agent comprising a medium chain oil, wherein after a single administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (C.sub.max) of 17.beta.-estradiol of about 19 pg*hr/ml to about 29 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of 17.beta.-estradiol of about 75 pg*hr/ml to about 112 pg*hr/ml, wherein 17.beta.-estradiol is the only active hormone in the pessary.

2. The pessary of claim 1, wherein administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (C.sub.max) of estrone of about 9 pg*hr/ml to about 14 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of estrone of about 43 pg*hr/ml to about 65 pg*hr/ml.

3. The pessary of claim 1, wherein administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (Cmax) of estrone sulfate of about 416 pg*hr/ml to about 613 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of estrone sulfate of about 3598 pg*hr/ml to about 5291 pg*hr/ml.

4. A pessary comprising about 10 .mu.g of 17.beta.-estradiol in a solubilizing agent comprising a medium chain oil, wherein after a single administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (C.sub.max) of 17.beta.-estradiol of about 12 pg*hr/ml to about 18 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of 17.beta.-estradiol of about 42 pg*hr/ml to about 63 pg*hr/ml, wherein 17.beta.-estradiol is the only active hormone in the pessary.

5. The pessary of claim 4, wherein the pessary further provides a corrected geometric mean time to peak plasma concentration (T.sub.max) of 17.beta.-estradiol of about 1 hrs to about 3 hrs.

6. The pessary of claim 4, wherein administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (C.sub.max) of estrone of about 4 pg*hr/ml to about 7 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of estrone of about 20 pg*hr/ml to about 31 pg*hr/ml.

7. The pessary of claim 6, wherein the pessary further provides a corrected geometric mean time to peak plasma concentration (T.sub.max) of estrone of about 4 hrs to about 8 hrs.

8. The pessary of claim 4, wherein administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (C.sub.max) of estrone sulfate of about 10 pg*hr/ml to about 16 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of estrone sulfate of about 56 pg*hr/ml to about 84 pg*hr/ml.

9. The pessary of claim 8, wherein the pessary further provides a corrected geometric mean time to peak plasma concentration (T.sub.max) of estrone sulfate of about 4 hrs to about 7 hrs.

10. A pessary comprising about 4 .mu.g of 17.beta.-estradiol in a solubilizing agent comprising a medium chain oil, wherein after a single administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (Cmax) of 17.beta.-estradiol of about 4 pg*hr/ml to about 8 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of 17.beta.-estradiol of about 16 pg*hr/ml to about 26 pg*hr/ml, wherein 17.beta.-estradiol is the only active hormone in the pessary.

11. The pessary of claim 10, wherein the pessary further provides a corrected geometric mean time to peak plasma concentration (T.sub.max) of 17.beta.-estradiol of about 0.25 hrs to about 2 hrs.

12. The pessary of claim 10, wherein administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (C.sub.max) of estrone of about 1 pg*hr/ml to about 3 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of estrone of about 8 pg*hr/ml to about 13 pg*hr/ml.

13. The pessary of claim 12, wherein the pessary further provides a corrected geometric mean time to peak plasma concentration (T.sub.max) of estrone of about 1 hrs to about 4 hrs.

14. The pessary of claim 10, wherein administration of the pessary to a patient provides, in a plasma sample from the patient: 1) a corrected geometric mean peak plasma concentration (C.sub.max) of estrone sulfate of about 4 pg*hr/ml to about 7 pg*hr/ml; and 2) a corrected geometric mean area under the curve (AUC).sub.0-24 of estrone sulfate of about 22 pg*hr/ml to about 34 pg*hr/ml.

15. The pessary of claim 14, wherein the pessary further provides a corrected geometric mean time to peak plasma concentration (T.sub.max) of estrone sulfate of about 1 hrs to about 3 hrs.

16. The pessary of claim 1, wherein the medium chain oil comprises at least one C6-C12 fatty acid or a glycol, monoglyceride, diglyceride, or triglyceride ester thereof.

17. The pessary of claim 1, wherein the medium chain oil comprises a monoglyceride, diglyceride, or triglyceride ester of the at least one C6-C12 fatty acid.

18. The pessary of claim 4, wherein the medium chain oil comprises at least one C6-C12 fatty acid or a glycol, monoglyceride, diglyceride, or triglyceride ester thereof.

19. The pessary of claim 4, wherein the medium chain oil comprises a monoglyceride, diglyceride, or triglyceride ester of the at least one C6-C12 fatty acid.

20. The pessary of claim 10, wherein the medium chain oil comprises at least one C6-C12 fatty acid or a glycol, monoglyceride, diglyceride, or triglyceride ester thereof.

21. The pessary of claim 10, wherein the medium chain oil comprises a monoglyceride, diglyceride, or triglyceride ester of the at least one C6-C12 fatty acid.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
Harvard Business School
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.